Fenofibrate and Dyslipidemia: Still a Place in Therapy?

Drugs
Nicola TarantinoNatale Daniele Brunetti

Abstract

Dyslipidemia is one of the major cardiovascular risk factors, but beyond statin treatment-which represents the cornerstone of therapy-a relevant practical uncertainty regards the use of fibrate derivatives. In the lack of successful results from the main cardiovascular trials, guidelines recommend the use of peroxisome proliferator-activated receptor agonists in selected cases, i.e. patients with true atherogenic dyslipidemia. However, recent observations indicate that fenofibrate treatment may provide a reliable complementary support against residual cardiovascular risk. We therefore summarize current evidence on fenofibrate, seeking to provide an updated interpretation of recent studies in the field.

References

Nov 9, 2002·Lancet·Majid EzzatiUNKNOWN Comparative Risk Assessment Collaborating Group
Feb 8, 2005·The American Journal of Cardiology·Scott M GrundyJoanne Palmisano
Apr 4, 2006·The American Journal of Cardiology·David E CohenUNKNOWN National Lipid Association Statin Safety Task Force Liver Expert Panel
Jan 19, 2007·The New England Journal of Medicine·Parvez HossainMeguid El Nahas
Mar 21, 2007·The American Journal of Cardiology·Michael H DavidsonTerry A Jacobson
Jan 24, 2008·European Journal of Human Genetics : EJHG·Jennifer A SmithSharon L R Kardia
Feb 12, 2008·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·C Fernández-MirandaJ A Solís-Herruzo
Mar 8, 2008·Journal of Internal Medicine·C P Cannon
Apr 17, 2008·Cardiology in Review·Joshua RemickArthur Schwartzbard
Aug 5, 2009·The Journal of Toxicological Sciences·Akio KobayashiKayoko Shimoi
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
Jul 1, 2010·The New England Journal of Medicine·UNKNOWN ACCORD Study GroupLawrence J Fine
Nov 26, 2010·Current Opinion in Lipidology·Marshall ElamHenry Ginsberg
Nov 2, 2011·Internal and Emergency Medicine·Diego Vanuzzo
Feb 14, 2013·Primary Care·Robert H Nelson
Nov 18, 2014·Metabolic Syndrome and Related Disorders·Julian Halcox, Anoop Misra
Aug 4, 2015·Atherosclerosis·Jason A HarmerUNKNOWN FIELD Vascular Study Investigators
Oct 27, 2015·The Cochrane Database of Systematic Reviews·Deren WangMing Liu
Feb 9, 2016·Atherosclerosis·Fumiyoshi TsunodaBela F Asztalos
Jul 12, 2016·Journal of Atherosclerosis and Thrombosis·Shinichi OikawaUNKNOWN Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators
Sep 8, 2016·Nature·Richard Hodson
Dec 29, 2016·JAMA Cardiology·Marshall B ElamUNKNOWN ACCORDION Study Investigators
Mar 1, 2017·Vascular Health and Risk Management·Nicola TarantinoNatale Daniele Brunetti
Apr 25, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerMichael Davidson
May 24, 2017·European Heart Journal Supplements : Journal of the European Society of Cardiology·Roberto FerrariAlberico L Catapano
Jul 25, 2017·Clinical Pharmacology and Therapeutics·Daniel M RotroffUNKNOWN ACCORD/ACCORDion Investigators
Dec 1, 2017·Expert Review of Cardiovascular Therapy·Bogusław OkopieńAleksandra Bołdys
Apr 18, 2018·International Journal of Molecular Sciences·Margherita BottaMassimiliano Ruscica

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.